Stockreport

Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade) [Seeking Alpha]

Elevation Oncology, Inc. - Common stock  (ELEV) 
PDF Their flagship project, EO-3021, is a phase 1 study targeting Claudin-18.2 and has shown promising early results. Elevation Oncology is also exploring anti-HER3 ADCs [Read more]